Mitra Anirban P, Cote Richard J
Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
Urol Oncol. 2007 Jul-Aug;25(4):341-3. doi: 10.1016/j.urolonc.2007.05.004.
Recent advances behind the understanding of the molecular mechanisms of bladder tumorigenesis have contributed towards the identification of molecules that can act as potential therapeutic targets for novel agents. Concurrently, this has also led to the understanding that effective therapy for superficial and invasive bladder cancers will entail a combination of therapeutic agents that target multiple tumorigenic pathways. Management of bladder cancer patients, as is the case in many other solid tumors, may witness radical transformations in the coming years as we translate our molecular understanding of the disease into novel clinical trial designs and screening techniques.
对膀胱肿瘤发生分子机制理解的最新进展，有助于识别可作为新型药物潜在治疗靶点的分子。与此同时，这也使人们认识到，针对浅表性和浸润性膀胱癌的有效治疗将需要多种靶向多个致癌途径的治疗药物联合使用。与许多其他实体瘤一样，随着我们将对该疾病的分子理解转化为新的临床试验设计和筛查技术，未来几年膀胱癌患者的管理可能会发生根本性变革。
